Predicting risk of breast cancer in postmenopausal women by hormone receptor status

Journal of the National Cancer Institute

Volumn 99, Issue 22, 2007, Pages 1695-1705

  Chlebowski, Rowan T ^a   Anderson, Garnet L ^b   Lane, Dorothy S ^c   Aragaki, Aaron K ^b   Rohan, Thomas ^d   Yasmeen, Shagufta ^e   Sarto, Gloria ^f   Rosenberg, Carol A ^g   Hubbell, F Allan ^h  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^g Evanston Northwestern Healthcare ^*  (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER INVASION; CANCER RISK; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; INCIDENCE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK REDUCTION; ANAMNESIS; AREA UNDER THE CURVE; BIOPSY; BODY WEIGHT; BREAST TUMOR; CHEMISTRY; CLINICAL TRIAL; DRINKING BEHAVIOR; EPIDEMIOLOGY; ETHNIC GROUP; ETHNOLOGY; MIDDLE AGED; MOTOR ACTIVITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PAGET NIPPLE DISEASE; PREDICTION AND FORECASTING; QUESTIONNAIRE; RISK; RISK FACTOR; ROC CURVE; SMOKING; STATISTICAL MODEL; STATISTICS; UNITED STATES; WOMEN'S HEALTH;

AGED; ALCOHOL DRINKING; AREA UNDER CURVE; BIOPSY; BODY WEIGHT; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CONFOUNDING FACTORS (EPIDEMIOLOGY); ETHNIC GROUPS; FEMALE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; MODELS, STATISTICAL; MOTOR ACTIVITY; MULTIVARIATE ANALYSIS; ODDS RATIO; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; QUESTIONNAIRES; RECEPTORS, ESTROGEN; REPRODUCTIVE HISTORY; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SMOKING; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; WOMEN'S HEALTH;

EID: 38449116155     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djm224     Document Type: Article

References (48)

1. Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 1999;91:1541-8.
2. Freedman AN, Seminara D, Gail MH, Hartge P, Colditz GA, Ballard-Barbash R, et al. Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst 2005;97:715-23.
3. Chlebowski RT, Col N, Winer EP, Collyar DE, Cummings SR, Vogel VG, et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene and aromatase inhibition. J Clin Oncol 2002;20:3328-43.
4. Kinsinger LS, Harris R, Woolf SH, Sox HC, Lohr KN. Chemoprevention of breast cancer: a summary of the evidence for the US preventive services task force. Ann Intern Med 2002;137:59-69.
5. Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 2003;95:526-32.
6. Brewster AM, Christo DK, Lai H, Helzlsouer K. Breast carcinoma chemoprevention in the community setting. Estimating risks and benefits. Cancer 2005;103:1147-53.
7. Lewis CL, Kinsinger LS, Harris RP, Schwartz RJ. Breast cancer risk in primary care: implications for chemoprevention. Arch Intern Med 2004;164:1897-903.
8. Anderson GL, Manson J, Wallace R, Lund B, Hall D, Davis S, et al. Implementation of the Women's Health Initiative study design. Ann Epidemiol 2003;13:S5-17.
9. Hays J, Hunt JR, Hubbell FA, Anderson GL, Limmacher M, Allen C, et al. The Women's Health Initiative recruitment methods and results. Ann Epidemiol 2003;13( Suppl ):S18-77.
10. Langer RD, White E, Lewis CE, Kotchen JM, Hendrix SL, Trevisan M, et al. The Women's Health Initiative observational study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol 2003;13( Suppl ):S107-21.
11. Curb JD, McTiernan A, Heckbert SR, Kooperberg C, Stanford J, Nevitt M, et al. WHI Morbidity and Mortality Committee. Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol 2003;13( Suppl ):S122-8.
12. National Cancer Institute. About SEER. Available at:http://www.seer. cancer.gov/. [Last accessed: July 29 2007.]
13. Hosmer DW, Hosmer T, Le Cessie S, Lemeshow S. A comparison of goodness-of-fit tests for the logistic regression model. Stat Med 1997;16:965-80.
14. Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 2001;93:358-66.
15. Bondy ML, Lustbader ED, Halabi S, Ross E, Vogel VG. Validation of a breast cancer risk assessment model in women with a positive family history. J Natl Cancer Inst 1994;86:620-5.
16. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-86.
17. Wingo PA, Ory HW, Layde PM, Lee NC. The evaluation of the data collection process for a multicenter, population-based case-control design. Am J Epidemiol 1988;128:206-17.
18. Spiegelman D, Colditz GA, Hunter D, Hertzmark E. Validation of the Gail et al. model for predicting individual breast cancer risk. J Natl Cancer Inst 1994;86:600-7.
19. Porter PL, El-Bastawissi AY, Mandelson MT, Lin MG, Khalid N, Watney EA, et al. Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 1999;91:2020-8.
20. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 2004;96:218-28.
21. Levin DC, Rao VM, Frangos AJ, Parker L, Sunshine JH. Current practice patterns and recent trends in breast biopsy among radiologists and surgeons. J Am Coll Radiol 2006;3:707-9.
22. Ghosh K, Melton J III, Suman VJ, Grant CS, Sterioff S, Brandt KR, et al. Breast biopsy utilization. Arch Intern Med 2005;165:1593-8.
23. Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res 2006;8:R43.
24. Rosenberg LU, Einarsdottir K, Friman EI, Wedren S, Dickman PW, Hall P, et al. Risk factors for hormone receptor-defined breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2006;15:2482-8.
25. Chen WY, Colditz GA. Risk factors and hormone-receptor status: epidemiology, risk-prediction models and treatment implications for breast cancer. Nat Clin Pract Oncol 2007;4:415-23.
26. Kaplan CP, Haas JS, Pérez-Stable EJ, Gregorich SE, Somkin C, Des Jarlais G, et al. Breast cancer risk reduction options: awareness, discussion, and use among women from four ethnic groups. Cancer Epidemiol Biomarkers Prev 2006;15:162-6.
27. Fosket J. Constructing "high risk women": the development and standardization of a breast cancer risk assessment tool. Sci Technol Human Values 2004;29:291-313.
28. Savage L. Researchers wonder why high-risk women are not taking chemoprevention drugs [news]. J Natl Cancer Inst 2007;99:913-4.
29. Armstrong K, Quistberg DA, Micco E, Domchek S, Guerra C. Prescription of tamoxifen for breast cancer prevention by primary care physicians. Arch Intern Med 2006;166:2260-5.
30. Freedman AN, Seinara D, Gail MH, Hartge P, Colditz GA, Ballard-Barbash R, et al. Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst 2005;97:715-23.
31. Chlebowski RT, Chen Z, Anderson GL, Rohan T, Aragaki A, Lane D, et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 2005;97:1619-20.
32. Bondy ML, Newman LA. Breast cancer risk assessment models: applicability to African American women. Cancer 2003;97:230-5.
33. Newman LA, Gail MH, Selvan M, Bondy M, Rockhill B, Colditz GA, et al. Proposed revision of the Gail breast cancer risk assessment model for African American women: American Society of Clinical Oncology; 2003.
34. Adams-Campbell LL, Makambi KH, Palmer JR, Rosenberg L. Diagnostic accuracy of the Gail model in the Black Women's Health Study. Breast J 2007;13:332-6.
35. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
36. Vogel V, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen versus raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA 2006;295:2727-41.
37. Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, et al. Benign breast disease and the risk of breast cancer. N Engl J Med 2005;353:229-37.
38. Santen RJ, Mansel R. Benign breast disorders. N Engl J Med 2005;353:275-85.
39. Arpino G, Laucirica R, Elledge RM. Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med 2005;143:446-57.
40. The Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-16.
41. Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007;356:227-36.
42. Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR. Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. JAMA 1996;276:1404-8.
43. Tamimi RM, Byrne C, Colditz GA, Hankinson SE. Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2007;99:1178-87.
44. Cummings SR, Duong T, Kenyon T, Cauley JA, Whitehead M, Krueger KA. Multiple Outcomes of Raloxifene Evalution (MORE) Trial. Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 2002;287:216-20.
45. Beattie MS, Costantino JP, Cummings SR, Wickerham DL, Vogel VG, Dowsett M, et al. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1). J Natl Cancer Inst 2006;98:110-5.
46. Tice JA, Cummings SR, Ziv E, Kerlikowske K. Mammographic breast density and the Gail model for breast cancer risk prediction in a screening population. Breast Cancer Res Treat 2005;94:115-22.
47. Barlow WE, White E, Ballard-Barbash R, Vacek PM, Titus-Ernstoff L, Carney PA, et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst 2006;98:1204-14.
48. Chen J, Pee D, Ayyagari R, Graubard B, Schairer C, Bryne C, et al. Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst 2006;98:1215-26.